Hatch-Waxman Act and Orange Book, Purple Book overview MCQs With Answer

Introduction:

The Hatch-Waxman Act and the FDA’s Orange Book and Purple Book are foundational to modern pharmaceutical regulation and generic/biosimilar competition. This blog presents focused multiple-choice questions to help M.Pharm students master how the Hatch-Waxman framework created the ANDA pathway, paragraph certifications, patent litigation triggers and exclusivity mechanisms. It also clarifies the Orange Book’s role in listing approved small-molecule drugs, therapeutic equivalence codes and patent/exclusivity information, versus the Purple Book’s listing of licensed biological products and biosimilarity/interchangeability status. These MCQs emphasize regulatory nuance, practical implications for product approval strategies, and key timelines that affect market entry for generics and biosimilars.

Q1. What primary regulatory pathway did the Hatch-Waxman Act establish to allow generic versions of approved small-molecule drugs to reach the market more quickly?

• New Drug Application (NDA) full clinical trial pathway
• Abbreviated New Drug Application (ANDA) relying on bioequivalence data
• Biosimilar Biologics License Application (351(k))
• Over-the-counter monograph drug submission

Correct Answer: Abbreviated New Drug Application (ANDA) relying on bioequivalence data

Q2. Which of the following correctly describes a Paragraph IV certification under the Hatch-Waxman Act?

• The applicant certifies there is no patent information filed for the reference listed drug
• The applicant certifies the patent has already expired
• The applicant certifies the patent is invalid or will not be infringed by the generic product
• The applicant agrees to defer approval until the listed patent’s expiration date

Correct Answer: The applicant certifies the patent is invalid or will not be infringed by the generic product

Q3. What regulatory consequence normally follows when a patent owner files a patent infringement suit within 45 days of receiving a Paragraph IV notice?

• A permanent injunction preventing FDA approval of the ANDA
• A 30-month automatic stay of FDA approval unless court rules earlier
• An immediate award of 180-day exclusivity to the ANDA filer
• A requirement that the ANDA applicant submit new clinical trials

Correct Answer: A 30-month automatic stay of FDA approval unless court rules earlier

Q4. Which exclusivity period is typically granted to a new chemical entity (NCE) under the Hatch-Waxman framework?

• 3 years
• 5 years
• 7 years
• 10 years

Correct Answer: 5 years

Q5. The 180-day exclusivity for the first approved generic under Hatch-Waxman is primarily awarded to which type of applicant?

• The first applicant to file a complete ANDA with a Paragraph IV certification
• The first applicant to submit a full NDA relying on original clinical data
• Any ANDA applicant approved within the first year after patent expiry
• The generic manufacturer that pays a fee to the reference sponsor

Correct Answer: The first applicant to file a complete ANDA with a Paragraph IV certification

Q6. What is the primary purpose of the FDA Orange Book?

• To list licensed biological products and interchangeability determinations
• To catalog over-the-counter monograph ingredients
• To list approved drug products with therapeutic equivalence evaluations, patent and exclusivity information for small-molecule drugs
• To publish FDA inspection and warning letter summaries

Correct Answer: To list approved drug products with therapeutic equivalence evaluations, patent and exclusivity information for small-molecule drugs

Q7. In the Orange Book, what does a therapeutic equivalence code beginning with “AB” generally indicate?

• The product is not bioequivalent and is therapeutically inequivalent
• The product is therapeutically equivalent and substitutable for the reference listed drug
• The product is a biologic and listed incorrectly in the Orange Book
• The product requires additional clinical trials for approval

Correct Answer: The product is therapeutically equivalent and substitutable for the reference listed drug

Q8. Which statement about Orange Book patent listings is accurate?

• The FDA independently verifies every patent submission for validity before listing
• Only patents that relate to the active ingredient can be listed
• Patent and exclusivity information is submitted by the NDA holder and FDA does not determine patent validity when listing
• Patents in the Orange Book automatically block generic approval until they expire

Correct Answer: Patent and exclusivity information is submitted by the NDA holder and FDA does not determine patent validity when listing

Q9. Which exclusivity confers an additional 6 months of marketing exclusivity when pediatric studies are completed per FDA written request?

• New chemical entity exclusivity
• Pediatric exclusivity
• Orphan drug exclusivity
• 180-day first-filer exclusivity

Correct Answer: Pediatric exclusivity

Q10. Which of the following is true about the FDA Purple Book?

• It lists approved small-molecule drugs and their therapeutic equivalence codes
• It lists licensed biological products, including biosimilars and interchangeability determinations
• It provides patent lists for biologics similar to those in the Orange Book
• It is maintained by the USP and not FDA

Correct Answer: It lists licensed biological products, including biosimilars and interchangeability determinations

Q11. The Biologics Price Competition and Innovation Act (BPCIA) created which abbreviated approval pathway for biosimilars?

• ANDA (505(j)) pathway
• 505(b)(2) hybrid pathway
• 351(k) biosimilar pathway
• NDA 505(b)(1) full pathway

Correct Answer: 351(k) biosimilar pathway

Q12. What regulatory distinction does an FDA interchangeability designation provide for a biosimilar?

• It makes the biosimilar exempt from patent litigation
• It permits pharmacist-level substitution for the reference product subject to state law
• It shortens the exclusivity period for the reference biologic
• It indicates the biosimilar used identical manufacturing facilities as the reference

Correct Answer: It permits pharmacist-level substitution for the reference product subject to state law

Q13. Which exclusivity is typically granted for drugs that treat rare diseases under the Orphan Drug Act?

• 3 years
• 5 years
• 7 years
• 10 years

Correct Answer: 7 years

Q14. Under Hatch-Waxman, which certification indicates the ANDA applicant will seek approval effective on the patent expiry date?

• Paragraph I
• Paragraph II
• Paragraph III
• Paragraph IV

Correct Answer: Paragraph III

Q15. If a generic ANDA filer submits a Paragraph IV certification and later prevails in court finding the listed patent invalid, what is a likely market outcome?

• The ANDA remains permanently barred from approval by FDA
• The FDA can approve the ANDA and the generic can enter the market earlier than patent expiration
• The ANDA filer must still conduct new pivotal clinical trials before approval
• The reference NDA is automatically withdrawn from the Orange Book

Correct Answer: The FDA can approve the ANDA and the generic can enter the market earlier than patent expiration

Q16. Which statement best reflects differences between the Orange Book and Purple Book?

• Both books list small molecules and biologics interchangeably
• The Orange Book lists small-molecule drug patents and TE codes; the Purple Book lists licensed biologics and biosimilarity/interchangeability
• The Purple Book contains therapeutic equivalence ratings for generic small molecules
• The Orange Book is a commercial directory maintained by industry, not FDA

Correct Answer: The Orange Book lists small-molecule drug patents and TE codes; the Purple Book lists licensed biologics and biosimilarity/interchangeability

Q17. Regarding patent listing timing, which is true about when NDA sponsors typically submit patents for listing in the Orange Book?

• Sponsors never list patents; FDA adds patents independently
• Sponsors submit patents and patent information for listing when appropriate during the post-approval lifecycle
• Patents must be listed before FDA grants the original NDA approval
• Patents are listed only after all pediatric studies are completed

Correct Answer: Sponsors submit patents and patent information for listing when appropriate during the post-approval lifecycle

Q18. What is a key practical reason generic companies monitor the Orange Book closely?

• To identify biologic interchangeability determinations for biosimilar planning
• To determine which reference drugs have therapeutic equivalence codes that preclude substitution
• To find patent and exclusivity listings that affect timing and strategy for ANDA filing and potential Paragraph IV challenges
• To obtain clinical safety data on the reference product for new drug development

Correct Answer: To find patent and exclusivity listings that affect timing and strategy for ANDA filing and potential Paragraph IV challenges

Q19. Which legal mechanism provided by BPCIA relates to patent dispute resolution between a reference biologic sponsor and a biosimilar applicant?

• ANDA 180-day exclusivity process
• The “patent dance” information-exchange and litigation sequencing provisions (statutory framework)
• Pediatric exclusivity correspondence
• Orphan drug filing waiver

Correct Answer: The “patent dance” information-exchange and litigation sequencing provisions (statutory framework)

Q20. Which of the following is NOT typically contained in the Purple Book entries?

• Licensed biological product name and BLA number
• Whether the product is biosimilar or interchangeable with a reference product
• Exhaustive patent information and listings analogous to the Orange Book patents
• Dates of licensure and reference product relationships

Correct Answer: Exhaustive patent information and listings analogous to the Orange Book patents

Download